Human toll-like receptor (hTLR)-8 is expressed in myeloid dendritic cells, monocytes, and monocytederived dendritic cells. Engagement by TLR8 agonists evokes a distinct cytokine profile which favors the development of type 1 helper T cells. Focused exploration of structure-activity relationships in the imidazoquinolines has led to the identification of several novel human TLR8-specific agonists. The synthetic procedures for best-in-class analogues encompassing four chemotypes are described.
|Original language||English (US)|
|Title of host publication||Methods in Molecular Biology|
|Publisher||Humana Press Inc.|
|Number of pages||16|
|State||Published - 2017|
|Name||Methods in Molecular Biology|
Bibliographical noteFunding Information:
This work was supported by NIH/NIAID contracts HSN272200900033C and HHSN272201400056C.
© Springer Science+Business Media New York 2017.
Copyright 2018 Elsevier B.V., All rights reserved.
- Innate immunity
- TLR8 agonists
- Vaccine adjuvants